NCT06109402View on ClinicalTrials.gov

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2030

Conditions
Stage II-IIIB(N2) Non-small Cell Lung Cancer
Interventions
DRUG

TQB2450

Specified dose on specified days

DRUG

Carboplatin

Specified dose on specified days

DRUG

Pemetrexed

Specified dose on specified days

DRUG

Nab-paclitaxel

Specified dose on specified days

PROCEDURE

Surgery

Surgery for II-IIIB (N2) non-small cell lung cancer

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06109402 - Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter